ArQule To Report Second Quarter 2016 Financial Results On

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016

BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq: ARQL ) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday, August 3, 2016.  The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. 

The live webcast can be accessed in the “Investors & Media” section of our website, www.arqule.com , under “Events & Presentations”. You may also listen to the call by dialing (877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, www.arqule.com , under “Events and Presentations”.

About ArQule

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our proprietary clinical-stage pipeline consists of four drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s lead product, in phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase, for second-line treatment of hepatocellular carcinoma in partnership with Daiichi Sankyo in the West and Kyowa Hakko Kirin in Asia. ArQule’s proprietary pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, in phase 1 for multiple oncology indications as well as ultra-rare Proteus syndrome, in partnership with the National Institutes of Health (NIH); ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for iCCA and in phase 1b for multiple oncology indications; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. 

Contact:  Dawn Schottlandt                                 Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300  www.arqule.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 120

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 65

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 46

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 100

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 143

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 139

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 75

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading

Top 5 Most Recently Viewed Articles

Twist Bioscience Set to Showcase Innovations at J.P. Morgan Event

Updated Category News Views 105

Twist Bioscience to Present at Renowned Healthcare Conference Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the synthetic biology and genomics field, has announced an upcoming presentation at the annual J.P. Morgan Healthcare Conference. This significant event is slated for January, and it serves as a vital platform for the company to showcase its...

Continue Reading
Leidos Secures Major NSA Contract Worth $390 Million

Updated Category News Views 154

Leidos Wins $390 Million NSA Signals Intelligence Contract Leidos, a prominent player in the defense and technology sectors, has recently secured a significant contract to enhance the capabilities of the National Security Agency (NSA) in the field of signals intelligence (SIGINT). This contract, valued at $390 million, will span an initial year with four additional...

Continue Reading
Devin Shanahan's Strategic Innovations in Global Trade Adaptation

Updated Category News Views 165

Adapting to Global Trade Challenges In a rapidly changing trade landscape, Devin Shanahan, co-founder of the innovative consumer brand Funtazma, is leading thoughtful changes in supply chain management due to the growing impact of U.S.-China trade tensions. With a wealth of experience in scaling consumer brands through global sourcing, Shanahan has been pivotal in guiding...

Continue Reading
Animal Nutrition Chemicals Market Insights and Growth Prospects

Updated Category News Views 185

Animal Nutrition Chemicals Market Overview The rapidly evolving animal nutrition chemicals market is poised for remarkable growth. As the need for high-quality and nutritious animal feed continues to escalate, this sector is likely to see significant changes and expansion. Comprehensive analyses reveal a bright future as industry players adapt to shifting demands and...

Continue Reading
Investors Ensnared in Orthofix Securities Fraud Case Seek Justice

Updated Category News Views 49

Understanding the Orthofix Securities Fraud Case Recently, investors in Orthofix Medical Inc. were informed about a serious legal action involving alleged securities fraud. The Schall Law Firm, which advocates for shareholder rights, is leading a class action lawsuit that addresses the alleged missteps by Orthofix during a specific time frame. It’s important for...

Continue Reading